** Shares of drug developer Repare Therapeutics RPTX.O rise 18% to $1.68 in extended trading
** RPTX licensed its cancer drug, lunresertib, to Swiss-based private firm Debiopharm for worldwide development and commercialization
** RPTX will receive $10 million upfront and could earn up to $257 million in milestone payments and royalties
** Debiopharm plans to combine lunresertib with its own drug Debio 0123 for cancer treatment
** Stock up 9.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.